ReviewFrontiers in pharmacology2018
Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Serological Biomarkers and Diversion Colitis: Changes after Stimulation with Probiotics.Biomolecules · 2021Trial
- Variation in Microbiome Composition and Faecal Metabolites Are Associated With Differential Susceptibility to DSS-Induced Colitis.Immunology · 2026Article
- Fluoroscopic control of a magnetorobotic capsule for precision gastrointestinal sampling and delivery.iScience · 2026Article
- Engineered probiotics platform for oral delivery of antibody as a high-compliance alternative for immune-mediated inflammatory diseases.Cell reports. Medicine · 2026Article
- Microbiota-Driven Strategies for Managing IBD-Associated Risks: From Infections to Mental Health.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploring the microbial basis of postbiotic and paraprobiotic therapy in ulcerative colitis.Archives of microbiology · 2025Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- The hidden piece in inflammatory bowel diseases: The significance of intestinal mucus in mediating the bacteria-cells crosstalk.Materials today. Bio · 2025Review
- Prebiotics and Probiotics Supplementation in Pigs as a Model for Human Gut Health and Disease.Biomolecules · 2025Review
- Microbiome: A Key Regulator of Body-Brain Interactions.Advances in experimental medicine and biology · 2025Review
- Recent Advances in Gut Microbiome Modulation: Effect of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Inflammatory Bowel Disease Prevention and Treatment.Current microbiology · 2024Review
- Transcriptional Responses ofBiology · 2024Article
- Review
- Review
- Editorial: Immunometabolism: bridging the gap between immunology and nutrition.Frontiers in nutrition · 2024Article
- Gut Protective Effect from Newly Isolated Bacteria as Probiotics against Dextran Sulfate Sodium and Carrageenan-Induced Ulcerative Colitis.Microorganisms · 2023Article
- Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.Cell host & microbe · 2023Article
- BothNutrients · 2023Article
- Alleviation of DSS-induced colitis in mice by a new-isolatedFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a group of multifactorial and inflammatory infirmities comprised of two main entities: Ulcerative colitis (UC) and Crohn's disease (CD). Classic strategies to treat IBD are focused on decreasing inflammation besides inducing and extending disease remission. However, these approaches have several limitations such as low responsiveness, excessive immunosuppression, and refractoriness. Despite the multifactorial causality of IBD, immune disturbances and intestinal dysbiosis have been suggested as the central players in disease pathogenesis. Hence, therapies aiming at modulating intestinal microbial composition may represent a promising strategy in IBD control. Fecal microbiota transplantation (FMT) and probiotics have been explored as promising candidates to reestablish microbial balance in several immune-mediated diseases such as IBD. These microbial-based therapies have demonstrated the ability to reduce both the dysbiotic environment and production of inflammatory mediators, thus inducing remission, especially in UC. Despite these promising results, there is still no consensus on the relevance of such treatments in IBD as a potential clinical strategy. Thus, this review aims to critically review and describe the use of FMT and probiotics to treat patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.